Effect of picumast dihydrochloride on antigen-induced early and late airway responses in allergic sheep

W. M. Abraham

Research output: Contribution to journalArticle

Abstract

In this study the effects of picumast dihydrochloride (3,4-dimethyl-7-[4-(4-chlorobenzyl)piperazine-1-yl]propoxycoumarine dihydrochloride) a novel antiallergic agent, on antigen-induced early and late responses in allergic sheep were examined. For all studies picumast dihydrochloride was administered as an aerosol ~20 min before airway challenge with Ascaris suum antigen. Allergic sheep were challenged on four occasions each ≥ 14 days apart: one placebo trial and after 1 mg, 2.5 mg, and 15 mg picumast dihydrochloride aerosol (total dose nebulized). Specific lung resistance (SR1) was used as an index of the airway response to antigen and was measured before and serially after antigen challenge. In the placebo trial (n = 11) antigen challenge resulted in significant early and late airway responses (i.e. 382% and 185% increases in SR1, respectively). Picumast dihydrochloride at 1.0 mg (n = 7) did not protect against the antigen-induced increases in SR(L). At 2.5 mg (n = 7), picumast dihydrochloride gave 48% and 55% (both p < 0.05) protection against the early and late airway responses, respectively. These effects were slightly enhanced with 5 mg picumast dihydrochloride (n = 7) giving 63% protection against the early response and 81% against the late response. These results suggest that the antiallergic agent picumast dihydrochloride may provide some benefit in the treatment of allergic airway disease.

Original languageEnglish
Pages (from-to)1328-1331
Number of pages4
JournalArzneimittel-Forschung/Drug Research
Volume39
Issue number10 A
StatePublished - Jan 1 1989
Externally publishedYes

Fingerprint

Sheep
Antigens
Anti-Allergic Agents
Aerosols
Placebos
Ascaris suum
picumast
Lung

Keywords

  • Airway responses, antigen-induced, early/late, experimental
  • Picumast dihydrochloride, pharmacology

ASJC Scopus subject areas

  • Chemistry(all)
  • Organic Chemistry
  • Drug Discovery
  • Pharmacology

Cite this

Effect of picumast dihydrochloride on antigen-induced early and late airway responses in allergic sheep. / Abraham, W. M.

In: Arzneimittel-Forschung/Drug Research, Vol. 39, No. 10 A, 01.01.1989, p. 1328-1331.

Research output: Contribution to journalArticle

@article{7c2f7a2eeb5b435eb4dfc7057d939bc0,
title = "Effect of picumast dihydrochloride on antigen-induced early and late airway responses in allergic sheep",
abstract = "In this study the effects of picumast dihydrochloride (3,4-dimethyl-7-[4-(4-chlorobenzyl)piperazine-1-yl]propoxycoumarine dihydrochloride) a novel antiallergic agent, on antigen-induced early and late responses in allergic sheep were examined. For all studies picumast dihydrochloride was administered as an aerosol ~20 min before airway challenge with Ascaris suum antigen. Allergic sheep were challenged on four occasions each ≥ 14 days apart: one placebo trial and after 1 mg, 2.5 mg, and 15 mg picumast dihydrochloride aerosol (total dose nebulized). Specific lung resistance (SR1) was used as an index of the airway response to antigen and was measured before and serially after antigen challenge. In the placebo trial (n = 11) antigen challenge resulted in significant early and late airway responses (i.e. 382{\%} and 185{\%} increases in SR1, respectively). Picumast dihydrochloride at 1.0 mg (n = 7) did not protect against the antigen-induced increases in SR(L). At 2.5 mg (n = 7), picumast dihydrochloride gave 48{\%} and 55{\%} (both p < 0.05) protection against the early and late airway responses, respectively. These effects were slightly enhanced with 5 mg picumast dihydrochloride (n = 7) giving 63{\%} protection against the early response and 81{\%} against the late response. These results suggest that the antiallergic agent picumast dihydrochloride may provide some benefit in the treatment of allergic airway disease.",
keywords = "Airway responses, antigen-induced, early/late, experimental, Picumast dihydrochloride, pharmacology",
author = "Abraham, {W. M.}",
year = "1989",
month = "1",
day = "1",
language = "English",
volume = "39",
pages = "1328--1331",
journal = "Drug Research",
issn = "2194-9379",
publisher = "Thieme",
number = "10 A",

}

TY - JOUR

T1 - Effect of picumast dihydrochloride on antigen-induced early and late airway responses in allergic sheep

AU - Abraham, W. M.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - In this study the effects of picumast dihydrochloride (3,4-dimethyl-7-[4-(4-chlorobenzyl)piperazine-1-yl]propoxycoumarine dihydrochloride) a novel antiallergic agent, on antigen-induced early and late responses in allergic sheep were examined. For all studies picumast dihydrochloride was administered as an aerosol ~20 min before airway challenge with Ascaris suum antigen. Allergic sheep were challenged on four occasions each ≥ 14 days apart: one placebo trial and after 1 mg, 2.5 mg, and 15 mg picumast dihydrochloride aerosol (total dose nebulized). Specific lung resistance (SR1) was used as an index of the airway response to antigen and was measured before and serially after antigen challenge. In the placebo trial (n = 11) antigen challenge resulted in significant early and late airway responses (i.e. 382% and 185% increases in SR1, respectively). Picumast dihydrochloride at 1.0 mg (n = 7) did not protect against the antigen-induced increases in SR(L). At 2.5 mg (n = 7), picumast dihydrochloride gave 48% and 55% (both p < 0.05) protection against the early and late airway responses, respectively. These effects were slightly enhanced with 5 mg picumast dihydrochloride (n = 7) giving 63% protection against the early response and 81% against the late response. These results suggest that the antiallergic agent picumast dihydrochloride may provide some benefit in the treatment of allergic airway disease.

AB - In this study the effects of picumast dihydrochloride (3,4-dimethyl-7-[4-(4-chlorobenzyl)piperazine-1-yl]propoxycoumarine dihydrochloride) a novel antiallergic agent, on antigen-induced early and late responses in allergic sheep were examined. For all studies picumast dihydrochloride was administered as an aerosol ~20 min before airway challenge with Ascaris suum antigen. Allergic sheep were challenged on four occasions each ≥ 14 days apart: one placebo trial and after 1 mg, 2.5 mg, and 15 mg picumast dihydrochloride aerosol (total dose nebulized). Specific lung resistance (SR1) was used as an index of the airway response to antigen and was measured before and serially after antigen challenge. In the placebo trial (n = 11) antigen challenge resulted in significant early and late airway responses (i.e. 382% and 185% increases in SR1, respectively). Picumast dihydrochloride at 1.0 mg (n = 7) did not protect against the antigen-induced increases in SR(L). At 2.5 mg (n = 7), picumast dihydrochloride gave 48% and 55% (both p < 0.05) protection against the early and late airway responses, respectively. These effects were slightly enhanced with 5 mg picumast dihydrochloride (n = 7) giving 63% protection against the early response and 81% against the late response. These results suggest that the antiallergic agent picumast dihydrochloride may provide some benefit in the treatment of allergic airway disease.

KW - Airway responses, antigen-induced, early/late, experimental

KW - Picumast dihydrochloride, pharmacology

UR - http://www.scopus.com/inward/record.url?scp=0024399041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024399041&partnerID=8YFLogxK

M3 - Article

C2 - 2576357

AN - SCOPUS:0024399041

VL - 39

SP - 1328

EP - 1331

JO - Drug Research

JF - Drug Research

SN - 2194-9379

IS - 10 A

ER -